How do genetic variants affect our interpretation of non-invasive tests for non-alcoholic fatty liver disease?
Hye Won Lee1,2,3, Sang Hoon Ahn1,2,3
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
No abstract available in PubMed .
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
